Addex Therapeutics (ADXN) announced that its collaboration agreement with Indivior (INDV) for the discovery of novel oral gamma-aminobutyric acid subtype B, or GABAB, positive allosteric modulator, or PAM, drug candidates for the treatment of substance use disorder has been extended until June 30, 2024. As part of the extended agreement, Indivior has committed CHF 2.7M to support research and discovery activities during this period. Addex retains exclusive rights to advance its own independent GABAB PAM program and is developing compounds for the treatment of chronic cough.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADXN:
